Noncoding RNAs that associate with YB-1 alter proliferation in prostate cancer cells
- Teresa T. Liu1,6,
- Gustavo Arango-Argoty1,6,
- Zhihua Li1,6,
- Yuefeng Lin1,
- Sang Woo Kim1,
- Anne Dueck2,
- Fatih Ozsolak3,
- A. Paula Monaghan4,
- Gunter Meister2,
- Donald B. Defranco5 and
- Bino John1
- 1Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15260, USA
- 2University of Regensburg, Biochemistry I, 93053 Regensburg, Bavaria, Germany
- 3Helicos BioSciences Corporation, Cambridge, Massachusetts 02139, USA
- 4Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15260, USA
- 5Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15260, USA
- Corresponding authors: bino{at}pitt.edu, dod1{at}pitt.edu
-
↵6 These authors contributed equally to this work.
Abstract
The highly conserved, multifunctional YB-1 is a powerful breast cancer prognostic indicator. We report on a pervasive role for YB-1 in which it associates with thousands of nonpolyadenylated short RNAs that are further processed into small RNAs (smyRNAs). Many of these RNAs have previously been identified as functional noncoding RNAs. We identified a novel, abundant, 3′-modified short RNA antisense to Dicer1 (Shad1) that colocalizes with YB-1 to P-bodies and stress granules. The expression of Shad1 was shown to correlate with that of YB-1 and whose inhibition leads to an increase in cell proliferation. Additionally, Shad1 influences the expression of additional prognostic markers of cancer progression such as DLX2 and IGFBP2. We propose that the examination of these noncoding RNAs could lead to better understanding of prostate cancer progression.
Keywords
Footnotes
-
Article published online ahead of print. Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.045559.114.
- Received March 26, 2014.
- Accepted March 3, 2015.
This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.










